12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aranesp darbepoetin alfa: Phase III data

Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif.
Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan
Product: Aranesp darbepoetin alfa ( NESP) ( KRN321)
Business: Hematology
Molecular target: Erythropoietin (EPO) receptor
Description: Erythropoiesis stimulating protein
Indication: Treat anemia in heart failure patients
Endpoint: Composite of time to death from any cause or...

Read the full 268 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >